ACB vs. KNSA, GPCR, NRIX, ARQT, ARDX, INDV, ARVN, VIR, SNDX, and ANIP
Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Kiniksa Pharmaceuticals (KNSA), Structure Therapeutics (GPCR), Nurix Therapeutics (NRIX), Arcutis Biotherapeutics (ARQT), Ardelyx (ARDX), Indivior (INDV), Arvinas (ARVN), Vir Biotechnology (VIR), Syndax Pharmaceuticals (SNDX), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry.
Aurora Cannabis vs.
Aurora Cannabis (NASDAQ:ACB) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.
Aurora Cannabis has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500.
Kiniksa Pharmaceuticals has higher revenue and earnings than Aurora Cannabis. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aurora Cannabis and Aurora Cannabis both had 9 articles in the media. Kiniksa Pharmaceuticals' average media sentiment score of 0.75 beat Aurora Cannabis' score of 0.33 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media.
Kiniksa Pharmaceuticals has a consensus price target of $36.60, suggesting a potential upside of 85.41%. Given Kiniksa Pharmaceuticals' higher probable upside, analysts clearly believe Kiniksa Pharmaceuticals is more favorable than Aurora Cannabis.
Aurora Cannabis has a net margin of 0.42% compared to Kiniksa Pharmaceuticals' net margin of -2.36%. Aurora Cannabis' return on equity of 0.59% beat Kiniksa Pharmaceuticals' return on equity.
Aurora Cannabis received 213 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. However, 65.02% of users gave Kiniksa Pharmaceuticals an outperform vote while only 59.63% of users gave Aurora Cannabis an outperform vote.
47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Aurora Cannabis and Kiniksa Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Aurora Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Aurora Cannabis Competitors List
Related Companies and Tools
This page (NASDAQ:ACB) was last updated on 2/17/2025 by MarketBeat.com Staff